Owlstone Medical, a Cambridge, UK diagnostics company, will collaborate with Shanghai’s Renji Hospital to conduct a clinical trial of Owlstone’s Breath Biopsy as an early detection device for lung cancer. The Breath Biopsy device measures volatile organic compounds — gaseous molecules in the breath that are produced by metabolic processes and can be used to detect cancer, inflammatory, infectious, metabolic, cardiovascular and respiratory diseases. The trial is supported by the Li Ka Shing Foundation.
Source: China Biotoday
